Sponsor Study ID:
A Multi-Center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-Cell Lymphoma That Express KIR3DL2
This is a multi-center phase 1b clinical trial. All patients will receive lacutamab until progression or unacceptable toxicity. Approximately 20 patients will be initially included in the study. Depending on safety profile and preliminary level of clinical activity, 20 more patients could be added.
If you would like to contact a MUSC study team member to learn more information about this study, click